Heterocyclic modulators of lipid synthesis
US-2024400552-A1 · Dec 5, 2024 · US
Azabenzimidazoles and their use as AMPA receptor modulators
US12139485B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12139485-B2 |
| Application number | US-202217967483-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 17, 2022 |
| Priority date | Apr 29, 2015 |
| Publication date | Nov 12, 2024 |
| Grant date | Nov 12, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
First claim
Opening claim text (preview).
What is claimed: 1. A method of conducting an imaging study, comprising administering to a subject in need thereof a composition comprising 2-(2-[18F]fluoro-4-pyridyl)-3-(7-methyl-1H-indazol-5-yl)-5-(trifluoromethyl)imidazo[4,5-b]pyridine, or a pharmaceutically acceptable salt, N-oxide, or solvate thereof. 2. The method of claim 1 , wherein the imaging study comprises PET or SPECT. 3. The method of claim 1 , wherein the imaging study comprises a drug or substrate tissue distribution assay. 4. The method of claim 1 , wherein the subject is in radioactive treatment.
Assignees
Inventors
Classifications
Drugs for disorders of the nervous system · CPC title
The ring being saturated · CPC title
with a four-membered ring · CPC title
the ring being unsaturated · CPC title
with a three-membered ring · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12139485B2 cover?
- Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
- Who is the assignee on this patent?
- Janssen Pharmaceutica Nv
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).